• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Tuesday

    2/28/23 12:56:40 PM ET
    $AFMD
    $ALIM
    $AMSWA
    $APTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AFMD alert in real time by email

     

    During Tuesday, 79 stocks hit new 52-week lows.

    Noteworthy Mentions In Today's 52-Week Lows:

    • Johnson & Johnson (NYSE:JNJ) was the biggest company in terms of market cap to set a new 52-week low.
    • China Pharma Holding (AMEX:CPHI) was the smallest firm on a market cap basis to set a new 52-week low.
    • Aptinyx (NASDAQ:APTX)'s stock traded down the lowest, falling 61.05% to reach a new 52-week low.
    • Atea Pharmaceuticals (NASDAQ:AVIR) shares bounced back the most, actually rising 0.0% after hiting a new 52-week low.

    On Tuesday, the following stocks broke to new 52-week lows:

    • Johnson & Johnson (NYSE:JNJ) stock drifted down 1.32% on Tuesday morning to hit a new 52-week low of $153.48.
    • Pfizer (NYSE:PFE) stock achieved a new 52-week low on Tuesday morning, hitting $40.09 and moving down 1.06%.
    • CVS Health (NYSE:CVS) shares moved down 1.0% on Tuesday to hit a new 52-week low of $83.92, drifting down 1.0%.
    • Dominion Energy (NYSE:D) stock broke to a new 52-week low of $55.33 on Tuesday. Shares of the company traded down 1.51%.
    • Royalty Pharma (NASDAQ:RPRX) stock achieved a new 52-week low on Tuesday morning, hitting $35.81 and moving down 0.17%.
    • Gen Digital (NASDAQ:GEN) stock hit $19.79 on Tuesday morning, setting a new 52-week low for a change of down 0.7%.
    • BILL Holdings (NYSE:BILL) shares reached a new 52-week low of $84.69 on Tuesday morning, moving up 0.54%.
    • SK Telecom Co (NYSE:SKM) shares fell to $18.27 on Tuesday, setting a new 52-week low with a shift of up 0.21%.
    • XP (NASDAQ:XP) shares moved up 0.57% on Tuesday to hit a new 52-week low of $12.19, drifting up 0.57%.
    • Kilroy Realty (NYSE:KRC) shares made a new 52-week low of $35.93 on Tuesday. The stock was up 0.32% for the day.
    • Vornado Realty (NYSE:VNO) stock hit a new 52-week low of $19.88. The stock was up 0.05% on the session.
    • Gol Intelligent Airlines (NYSE:GOL) shares set a new 52-week low of $2.17. The stock traded up 0.23%.
    • Lumen Technologies (NYSE:LUMN) stock set a new 52-week low of $3.30 on Tuesday, moving up 1.03%.
    • Hesai Gr (NASDAQ:HSAI) stock dropped to a yearly low on Tuesday of $17.80. Shares traded up 2.25%.
    • Thoughtworks Holding (NASDAQ:TWKS) stock achieved a new 52-week low on Tuesday morning, hitting $6.86 and moving down 20.02%.
    • Baytex Energy (NYSE:BTE) stock dropped to a yearly low on Tuesday of $3.89. Shares traded down 8.82%.
    • NetScout Systems (NASDAQ:NTCT) shares hit a yearly low of $27.95. The stock was down 1.06% on the session.
    • JBG SMITH Props (NYSE:JBGS) stock broke to a new 52-week low of $17.31 on Tuesday. Shares of the company traded down 0.77%.
    • Virtu Finl (NASDAQ:VIRT) stock hit a new 52-week low of $18.36. The stock was down 2.2% on the session.
    • Altice USA (NYSE:ATUS) stock drifted down 0.13% on Tuesday morning to hit a new 52-week low of $3.57.
    • ReNew Energy Glb (NASDAQ:RNW) shares were down 0.23% for the day, having made a 52-week low of $4.25.
    • ImmunityBio (NASDAQ:IBRX) shares reached a new 52-week low of $2.46 on Tuesday morning, moving down 1.98%.
    • Brandywine Realty Tr (NYSE:BDN) stock hit a yearly low of $5.92. The stock was down 0.33% for the day.
    • Cronos Group (NASDAQ:CRON) shares were down 5.48% for the day, having made a 52-week low of $1.97.
    • Mercer Intl (NASDAQ:MERC) stock dropped to a yearly low on Tuesday of $10.27. Shares traded down 2.33%.
    • Gladstone Commercial (NASDAQ:GOOD) shares were down 1.56% for the day, having made a 52-week low of $13.85.
    • Blink Charging (NASDAQ:BLNK) shares made a new 52-week low of $8.90 on Tuesday. The stock was down 0.22% for the day.
    • AudioCodes (NASDAQ:AUDC) stock hit a yearly low of $15.98. The stock was up 0.56% for the day.
    • Azul (NYSE:AZUL) shares made a new 52-week low of $4.03 on Tuesday. The stock was down 1.83% for the day.
    • American Software (NASDAQ:AMSWA) stock broke to a new 52-week low of $12.89 on Tuesday. Shares of the company traded up 2.7%.
    • Canoo (NASDAQ:GOEV) shares made a new 52-week low of $0.69 on Tuesday. The stock was up 4.47% for the day.
    • FiscalNote Holdings (NYSE:NOTE) shares fell to $2.39 on Tuesday, setting a new 52-week low with a shift of down 3.19%.
    • Surmodics (NASDAQ:SRDX) shares fell to $22.12 on Tuesday, setting a new 52-week low with a shift of down 0.05%.
    • Atea Pharmaceuticals (NASDAQ:AVIR) shares hit a yearly low of $3.52. The stock was 0.0% (flat) on the session.
    • Nektar Therapeutics (NASDAQ:NKTR) stock dropped to a yearly low on Tuesday of $1.37. Shares traded up 1.08%.
    • Etao International Co (NASDAQ:ETAO) stock dropped to a yearly low on Tuesday of $2.23. Shares traded down 7.68%.
    • Tucows (NASDAQ:TCX) shares reached a new 52-week low of $22.91 on Tuesday morning, moving down 1.15%.
    • Morgan Stanley India (NYSE:IIF) shares were down 0.2% for the day, having made a 52-week low of $19.75.
    • PIMCO California (NYSE:PCQ) shares set a new yearly low of $10.16 this morning. The stock was down 0.24% on the session.
    • Universal Electronics (NASDAQ:UEIC) shares moved down 1.06% on Tuesday to hit a new 52-week low of $12.80, drifting down 1.06%.
    • LL Flooring Holdings (NYSE:LL) shares were down 1.26% for the day, having made a 52-week low of $5.05.
    • Affimed (NASDAQ:AFMD) stock drifted down 0.28% on Tuesday morning to hit a new 52-week low of $0.89.
    • Eargo (NASDAQ:EAR) stock hit a yearly low of $5.92. The stock was down 3.68% for the day.
    • CURO Group Holdings (NYSE:CURO) shares hit a yearly low of $2.91. The stock was down 0.67% on the session.
    • Intercure (NASDAQ:INCR) shares made a new 52-week low of $2.50 on Tuesday. The stock was down 3.82% for the day.
    • Cumulus Media (NASDAQ:CMLS) shares reached a new 52-week low of $5.38 on Tuesday morning, moving down 0.9%.
    • Vintage Wine Estates (NASDAQ:VWE) shares set a new yearly low of $1.51 this morning. The stock was down 0.33% on the session.
    • Cazoo Gr (NYSE:CZOO) shares made a new 52-week low of $2.27 on Tuesday. The stock was down 1.9% for the day.
    • Chicken Soup for the Soul (NASDAQ:CSSE) shares moved down 0.69% on Tuesday to hit a new 52-week low of $4.14, drifting down 0.69%.
    • Cerberus Cyber Sentinel (NASDAQ:CISO) shares moved down 6.93% on Tuesday to hit a new 52-week low of $0.50, drifting down 6.93%.
    • Clough Global Dividend (AMEX:GLV) stock hit a yearly low of $6.01. The stock was 0.0% (flat) for the day.
    • GreenLight Biosciences (NASDAQ:GRNA) shares hit a yearly low of $0.45. The stock was down 5.39% on the session.
    • US Energy (NASDAQ:USEG) stock set a new 52-week low of $2.16 on Tuesday, moving down 0.45%.
    • Sono Group (NASDAQ:SEV) stock set a new 52-week low of $0.54 on Tuesday, moving up 3.62%.
    • MultiMetaVerse Holdings (NASDAQ:MMV) stock hit a yearly low of $1.42. The stock was down 3.38% for the day.
    • Lichen China (NASDAQ:LICN) stock dropped to a yearly low on Tuesday of $1.70. Shares traded down 2.78%.
    • Impel Pharmaceuticals (NASDAQ:IMPL) shares set a new 52-week low of $1.30. The stock traded down 3.68%.
    • Treasure Global (NASDAQ:TGL) shares set a new yearly low of $1.40 this morning. The stock was down 9.76% on the session.
    • Ascent Solar Technologies (NASDAQ:ASTI) stock broke to a new 52-week low of $0.48 on Tuesday. Shares of the company traded up 3.19%.
    • Aridis Pharmaceuticals (NASDAQ:ARDS) shares made a new 52-week low of $0.55 on Tuesday. The stock was down 1.22% for the day.
    • TuanChe (NASDAQ:TC) stock broke to a new 52-week low of $0.60 on Tuesday. Shares of the company traded down 2.06%.
    • Alimera Sciences (NASDAQ:ALIM) stock hit a yearly low of $2.00. The stock was down 5.4% for the day.
    • Bit Brother (NASDAQ:BTB) shares set a new yearly low of $1.36 this morning. The stock was up 2.19% on the session.
    • Jupiter Wellness (NASDAQ:JUPW) shares moved down 1.62% on Tuesday to hit a new 52-week low of $0.45, drifting down 1.62%.
    • Soligenix (NASDAQ:SNGX) shares were 0.0% (flat) for the day, having made a 52-week low of $3.30.
    • Integrated Media Tech (NASDAQ:IMTE) stock hit $0.52 on Tuesday morning, setting a new 52-week low for a change of up 0.17%.
    • WiSA Technologies (NASDAQ:WISA) shares made a new 52-week low of $4.20 on Tuesday. The stock was down 1.84% for the day.
    • Ensysce Biosciences (NASDAQ:ENSC) shares set a new 52-week low of $0.46. The stock traded up 2.6%.
    • SILO Pharma (NASDAQ:SILO) stock broke to a new 52-week low of $2.16 on Tuesday. Shares of the company traded down 0.45%.
    • Tivic Health Systems (NASDAQ:TIVC) shares reached a new 52-week low of $0.18 on Tuesday morning, moving down 6.7%.
    • Windtree Therapeutics (NASDAQ:WINT) shares set a new 52-week low of $5.60. The stock traded down 7.32%.
    • China Pharma Holding (AMEX:CPHI) stock hit a yearly low of $0.07. The stock was down 0.56% for the day.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $AFMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AFMD
    $ALIM
    $AMSWA
    $APTX

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    2/25/2026$25.00Underperform
    RBC Capital Mkts
    Kilroy Realty Corporation
    $KRC
    2/24/2026$29.00Neutral → Underperform
    Mizuho
    Pfizer Inc.
    $PFE
    2/20/2026$25.00Underweight
    Barclays
    SK Telecom Co. Ltd.
    $SKM
    2/18/2026Neutral → Underperform
    BofA Securities
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Nektar Therapeutics
    $NKTR
    2/10/2026Mkt Perform → Outperform
    William Blair
    Hesai Group
    $HSAI
    2/10/2026$31.50Outperform
    Macquarie
    BILL Holdings Inc.
    $BILL
    2/6/2026$50.00 → $46.00Market Perform
    BMO Capital Markets
    More analyst ratings

    $AFMD
    $ALIM
    $AMSWA
    $APTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Laberge Alice bought $1,900 worth of shares (1,000 units at $1.90) (SEC Form 4)

    4 - MERCER INTERNATIONAL INC. (0001333274) (Issuer)

    2/27/26 2:42:29 PM ET
    $MERC
    Paper
    Basic Materials

    Director Simon Barry J. sold $900,788 worth of shares (75,000 units at $12.01), decreasing direct ownership by 3% to 2,850,821 units (SEC Form 4)

    4 - ImmunityBio, Inc. (0001326110) (Issuer)

    2/26/26 8:12:26 PM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Kenost Jared Matthew claimed ownership of 29,388 shares (SEC Form 3)

    3 - Cronos Group Inc. (0001656472) (Issuer)

    2/26/26 5:30:45 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $AFMD
    $ALIM
    $AMSWA
    $APTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Pfizer with a new price target

    RBC Capital Mkts initiated coverage of Pfizer with a rating of Underperform and set a new price target of $25.00

    2/25/26 7:53:28 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kilroy Realty downgraded by Mizuho with a new price target

    Mizuho downgraded Kilroy Realty from Neutral to Underperform and set a new price target of $29.00

    2/24/26 7:43:49 AM ET
    $KRC
    Real Estate Investment Trusts
    Real Estate

    Barclays initiated coverage on Pfizer with a new price target

    Barclays initiated coverage of Pfizer with a rating of Underweight and set a new price target of $25.00

    2/20/26 8:25:15 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFMD
    $ALIM
    $AMSWA
    $APTX
    SEC Filings

    View All

    SEC Form 10-K filed by Pfizer Inc.

    10-K - PFIZER INC (0000078003) (Filer)

    2/26/26 12:44:01 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kilroy Realty Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - KILROY REALTY CORP (0001025996) (Filer)

    2/26/26 9:11:58 AM ET
    $KRC
    Real Estate Investment Trusts
    Real Estate

    SEC Form 10-K filed by Cronos Group Inc.

    10-K - Cronos Group Inc. (0001656472) (Filer)

    2/26/26 7:38:28 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $AFMD
    $ALIM
    $AMSWA
    $APTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Laberge Alice bought $1,900 worth of shares (1,000 units at $1.90) (SEC Form 4)

    4 - MERCER INTERNATIONAL INC. (0001333274) (Issuer)

    2/27/26 2:42:29 PM ET
    $MERC
    Paper
    Basic Materials

    Director Tisch Daniel R bought $696,250 worth of shares (25,000 units at $27.85), increasing direct ownership by 500% to 30,000 units (SEC Form 4)

    4 - VORNADO REALTY TRUST (0000899689) (Issuer)

    2/26/26 4:30:06 PM ET
    $VNO
    Real Estate Investment Trusts
    Real Estate

    Chief Financial Officer Gerson Gary bought $3,428 worth of shares (275 units at $12.46), increasing direct ownership by 1% to 23,475 units (SEC Form 4)

    4 - GLADSTONE COMMERCIAL CORP (0001234006) (Issuer)

    2/26/26 2:33:23 PM ET
    $GOOD
    Real Estate

    $AFMD
    $ALIM
    $AMSWA
    $APTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFMD
    $ALIM
    $AMSWA
    $APTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Follow-Through Leaders: Production Ramps, AI Alliances, Balance Sheet Strength

    DENVER, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Markets reward momentum and trends may sustain when execution follows headlines. Several companies are now moving beyond announcements and into operational validation, positioning themselves for potential continued follow-through. From biomaterials scale-up to enterprise AI deployment and disciplined capital allocation, these names are building narratives that extend beyond a single news cycle. Kraig Biocraft Laboratories: From Strategy to Scale Activity has accelerated at Kraig Biocraft Laboratories (OTCQB:KBLB) following confirmation that its 2026 production plan has officially transitioned from roadmap to execution. The company has moved bio

    2/27/26 9:45:46 AM ET
    $ENSC
    $PLTR
    $RXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology

    ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

    ImmunityBio, Inc. ((IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company's clinical trial pipeline, and to review financial results for the year ended December 31, 2025. Conference Call Details The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 3, 2026. Interested parties may access the conference call through our Investor Relations website, ir.immunitybio.com, under Company — Events & Presentations. Alternatively, individuals can access the call by dialing 1-844-539-3703 or 1-412-652-1273 (internationally).

    2/27/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar web

    2/26/26 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFMD
    $ALIM
    $AMSWA
    $APTX
    Leadership Updates

    Live Leadership Updates

    View All

    Kilroy Realty Corporation Announces Board Refreshment

    Kilroy Realty Corporation (NYSE:KRC) ("Kilroy" or the "Company") today announced leadership changes on the Company's Board of Directors (the "Board") and within its committees, including the appointment of Gary Stevenson as Chair of the Board, Edward Brennan, PhD, as Chair of the Audit Committee, and Jolie Hunt as Chair of the Executive Compensation Committee. In addition, the Company announced the appointment of two new Directors, Cia Buckley Marakovits and David Kieske, to the Company's Board. All leadership changes and new Director appointments were effective February 24, 2026. BOARD LEADERSHIP TRANSITION The Board has appointed Gary Stevenson as Chair of the Board, succeeding Edward

    2/26/26 9:05:00 AM ET
    $KRC
    Real Estate Investment Trusts
    Real Estate

    CISO Global Appoints Dhaval Damania as EVP of Cybersecurity & IT

    Experienced AI and enterprise IT operations leader joins Company to accelerate scalable growth, strengthen security architecture, and advance next-generation cyber software innovation Scottsdale, Ariz., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CISO Global, Inc. (NASDAQ:CISO) ("CISO Global" or the "Company"), a provider of AI-powered cybersecurity software and compliance services, today announced the appointment of Dhaval Damania as Executive Vice President of Cybersecurity & IT. This appointment reinforces its continued commitment to operational excellence, innovation, and scalable growth across its next-generation cybersecurity software portfolio. In this role, Damania will lead CISO Global's

    2/23/26 8:30:00 AM ET
    $CISO
    Professional Services
    Consumer Discretionary

    CISO Global Lands 30 Year Sales Veteran Michael Czerneda to Ignite the Next Wave of Software Growth

    New Vice President of Sales to accelerate software-driven growth across cyber services platform and insurance distribution channels  Scottsdale, Ariz., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CISO Global, Inc. (NASDAQ:CISO) ("CISO Global" or the "Company"), a provider of AI-powered cybersecurity software and compliance services, today announced the appointment of Michael Czerneda as Vice President of Sales. In this role, Czerneda will lead enterprise-wide sales initiatives as the Company accelerates its transition toward scalable, software-driven growth built on its established cyber services platform.  Czerneda brings more than 30 years of sales leadership experience spanning UCaaS, CCaaS, da

    2/18/26 8:30:00 AM ET
    $CISO
    Professional Services
    Consumer Discretionary

    $AFMD
    $ALIM
    $AMSWA
    $APTX
    Financials

    Live finance-specific insights

    View All

    ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

    ImmunityBio, Inc. ((IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company's clinical trial pipeline, and to review financial results for the year ended December 31, 2025. Conference Call Details The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 3, 2026. Interested parties may access the conference call through our Investor Relations website, ir.immunitybio.com, under Company — Events & Presentations. Alternatively, individuals can access the call by dialing 1-844-539-3703 or 1-412-652-1273 (internationally).

    2/27/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar web

    2/26/26 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

    BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 5, 2026, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2025, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Phar

    2/26/26 7:00:00 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFMD
    $ALIM
    $AMSWA
    $APTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ReNew Energy Global plc

    SC 13D/A - ReNew Energy Global plc (0001848763) (Subject)

    12/10/24 7:57:27 PM ET
    $RNW
    Electric Utilities: Central
    Utilities

    Amendment: SEC Form SC 13D/A filed by ReNew Energy Global plc

    SC 13D/A - ReNew Energy Global plc (0001848763) (Subject)

    12/10/24 7:53:40 PM ET
    $RNW
    Electric Utilities: Central
    Utilities

    Amendment: SEC Form SC 13D/A filed by ReNew Energy Global plc

    SC 13D/A - ReNew Energy Global plc (0001848763) (Subject)

    12/10/24 7:32:48 PM ET
    $RNW
    Electric Utilities: Central
    Utilities